Greater bioavailability of chelated compared with inorganic zinc in broiler chicks in the presence or absence of elevated calcium and phosphorus

James D Richards
Paula M Fisher
Joseph L Evans
Karen J Wedekind
Research and Development Department, Novus International Inc., Saint Charles, MO, USA

Abstract: Animal diets often contain antagonists that reduce bioavailability, thereby creating a deficiency. The bioavailability of Zn chelated to 2-hydroxy-4-(methylthio)butanoic acid (chelated Zn) was compared with Zn sulfate in broiler chicks in two dietary conditions: a Zn-deficient corn-soybean meal (C-SBM) diet and a Zn-deficient C-SBM diet containing elevated Ca and P as antagonists. In experiment 1, chicks were fed a common diet (19 mg Zn/kg diet) through day 8, and then a Zn-unsupplemented (21 mg Zn/kg diet; 0.82% Ca, 0.47% available P) C-SBM basal or the basal supplemented with 5, 10, 15, 20, or 30 mg Zn/kg diet as chelated Zn or Zn sulfate for 6 days. Common-intercept, multiple linear regression slope-ratio analysis indicated significantly greater Zn bioavailability for chelated Zn relative to Zn sulfate as judged by: total tibia Zn (µg) (161%; P=0.001); tibia zinc concentration (µg/g; 165%, P=0.0009); and small intestinal metallothionein mRNA expression (248%; P=0.009). In experiment 2, chicks were fed a Zn-deficient (24 mg Zn/kg diet) common diet, then fed a C-SBM basal elevated in Ca and P (27 mg Zn/kg diet; 1.2% Ca, 1% available P), or the basal supplemented with 15 or 30 mg Zn/kg diet as Zn sulfate or 7.5, 15, or 30 mg Zn/kg diet as chelated Zn. Zn sulfate was antagonized to a greater extent than Zn chelate. Bioavailability of chelated Zn relative to Zn sulfate was 441% (P=0.0063; µg total tibia Zn), 307% (P=0.0066; µg/g tibia Zn), and 426% (P=0.0041; metallothionein). Thus, feeding chelated Zn offers advantages over inorganic Zn, especially in diets containing high levels of Ca and P, which is a common occurrence in pet food and in livestock diets.

Keywords: antagonism, broilers, chelate, metallothionein, minerals

Introduction

Zinc impacts a wide variety of functions, including gene expression, DNA and protein synthesis, cell signaling, cell division and animal growth, immune development and function, synthesis of structural proteins such as collagen and keratin, bone and tissue development, reproduction, and defense against oxidative stress.1–11 Deficiency or marginal Zn status can negatively impact one or more of these processes. As such, Zn is supplemented in virtually all animal diets, either as inorganic trace mineral (ITM) salts (such as sulfates, chlorides, and oxides), and/or organic trace minerals (OTMs). While ITMs are inexpensive, it is generally accepted that they suffer from relatively poor bioavailability compared with some OTMs, primarily due to the numerous antagonisms and interactions between the ITMs and other components of the digesta, such as phytic acid and fiber.10,12,13 Other types of Zn antagonisms have been reported, including excesses of Ca and/or P.10,14–16

The antagonistic effect of excess Ca on Zn utilization is widely known, especially in the presence of phytate.17 Few studies, however, have evaluated the effects of P excess
on Zn bioavailability, and the results of these studies have been inconsistent. Studies demonstrating detrimental effects of excess P concluded that both Ca and P excess antagonized Zn independently of each other, but that the combination of Ca and P were additive. In addition, Zn antagonism occurred under both balanced and unequal Ca:P ratios. According to Heth et al., Ca decreased Zn absorption in the presence of 1% dietary P, but not when P was 0.3%–0.5%. Furthermore, detrimental effects of P occurred for both phytic acid P and inorganic P, and either form of inorganic P (eg, polyphosphates or orthophosphates) was antagonistic. Other studies, however, failed to show negative effects of P excess on Zn utilization. However, these latter studies suffered from insufficient statistical power, response variables with limited sensitivity to Zn deficiency, or utilized diets not deficient in Zn, thus having a limited likelihood of observing any effect.

It is widely accepted that a higher degree of nutrition is required to achieve the full genetic and economic potential of today’s livestock. Balancing both macrominerals and microminerals is a key component of optimizing nutritional health, whether it is the health of livestock, pets, or humans. Feeding higher levels of trace minerals is not a viable solution because this can lead to lower mineral bioavailability, increase environmental burden, and potentially even decrease animal performance. A more sustainable solution is to feed a more bioavailable source of trace minerals such as OTM. However, the literature indicates that not all OTMs are more available than the ITM salts.

Bioavailability can be defined as “the degree to which an ingested nutrient in a particular source is absorbed in a form that can be utilized in metabolism by the animal” in practice, relative bioavailability value (RBV), or the bioavailability of a nutrient within one source relative to the bioavailability of the same nutrient in a standard source, is measured. Measuring the deposition or storage of minerals into selected tissues is the most common variable measured in trace mineral RBV experiments; for example, tibia Zn is commonly cited for most Zn RBV studies. In addition, it has been reported that the expression levels of several genes and proteins increase or decrease rapidly depending on the Zn status of the animal.

Metallothionein (MT) mRNA and protein are both modulated by Zn absorption and status, and are frequently used as indices of Zn status or bioavailability in a wide variety of species. The primary objective of the studies described here was to compare the bioavailability of chelated Zn with that of Zn sulfate in chicks fed corn-soybean meal (C-SBM) diets both in the absence and presence of elevated Ca and P. Tibia Zn and small intestinal MT mRNA expression were used to measure Zn bioavailability.

Materials and methods

General
A Zn depletion–repletion broiler chick model was used to evaluate Zn bioavailability. Cobb 500 male broiler chicks were randomly assigned to dietary treatments in a randomized complete block design for each experiment. All birds were placed on a common, low Zn milo-soybean meal (SBM) pre-treatment diet (Table 1, 19 mg Zn/kg diet, experiment 1; 24 mg Zn/kg diet, experiment 2; Zn difference due to use of different ingredient lots) on day 0, and then switched to C-SBM treatment diets (Table 1) on day 8. The treatment diets were a Zn-unsupplemented C-SBM basal, or the basal supplemented with Zn as Zn sulfate ($\text{ZnSO}_4 \cdot \text{H}_2\text{O}$) or Zn methionine hydroxy analog chelate [Zn bis-(2-hydroxy-4-(methylthio)butanoic acid; ZnHMTBa; Novus International Inc., Saint Charles, MO, USA]. All diets were formulated based on standard US commercial nutrient specifications as reported in a leading agricultural survey with two exceptions: in experiment 2, the Ca and P were substantially elevated to provide a dietary antagonism for Zn, and in each trial, the Zn concentrations of the pre-treatment diet and several treatment diets were below the levels recommended by the National Research Council (NRC; 40 mg Zn/kg diet). There were six replicates (pens) per treatment, except for the basal (treatment 1, experiment 1 only) which had 12 replicates, with eight chicks per replicate. The small intestine (jejunum) was collected from one bird per pen (0, 15, and 30 mg Zn/kg diet supplemental Zn treatments; experiment 1) on day 11 (after 3 days on treatment diets) or two birds per pen (all treatments; experiment 2; also day 11) and assayed for MT expression as described below. On day 14 (after 6 days on the treatment diets), the birds were weighed, and the right and left tibias were collected (analyzed separately and averaged) from two birds per pen (all treatments) for Zn analysis by inductively coupled plasma optical emissions spectrometry, using an internally validated method based on AOAC 985.01. The timing of the intestinal and tibia collections was based on other published depletion–repletion trials in rodents and birds. All birds were raised in electrically heated brooders. Each pen was provided with water and an individual feeder. All birds were allowed to consume mash feed and water ad libitum. The animal protocols for all experiments were in accordance with the standard operating procedures of Novus International Inc., and complied with all federal and state statutes ensuring the humane and ethical treatment of experimental animals. All birds were observed at least twice.
daily and mortality was recorded. Body weight, cumulative gain, cumulative (mortality-corrected) gain to feed ratio, feed intake, and mortality were calculated for days 8–14.

Experiment 1
A total of 576 Cobb 500 male broiler chicks were switched to a C-SBM basal diet after an 8-day pre-feed (analyzed to contain 19 mg Zn/kg diet), and randomized to eleven dietary treatments using a randomized complete block design. The treatment diets included a Zn-unsupplemented basal (analyzed to contain 21 mg Zn/kg diet) or the basal supplemented with 5, 10, 15, 20, or 30 mg Zn/kg diet either as Zn sulfate or Zn methionine hydroxy analog chelate. Calcium, available P, and total P were 0.82%, 0.47%, and 0.72%, respectively. Phytate concentration was calculated to be 0.94%.

Experiment 2
A total of 288 Cobb 500 male broiler chicks were switched to a C-SBM basal diet after an 8-day pre-feed (analyzed to contain 24 mg Zn/kg diet), and randomized to six dietary treatments in a randomized complete block design. The treatment diets were a Zn-unsupplemented (analyzed to contain 27 mg Zn/kg diet) basal, or the basal supplemented with 15 or 30 mg Zn/kg diet as Zn sulfate or 7.5, 15, or 30 mg Zn/kg diet as chelated Zn. In experiment 2, Ca (1.2%) and P (available, 1%; total, 1.3%) were substantially elevated relative to the diets in experiment 1 through the inclusion of dicalcium phosphate. Phytate was calculated to be 0.95% compared with an analyzed concentration of 1.24%.

Metallothionein gene expression
A section of jejunum, immediately posterior to the duodenal loop and approximately 10 cm in length, was collected and rinsed gently with 3–4 mL of ice-cold saline. The jejunum was cut open lengthwise and placed mucosal side up on a clean cutting board. The mucosa from 6–8 cm of this section was scraped off with a glass slide and collected into 0.9 mL of RNA later (Ambion, Austin, TX, USA), stored at 4°C overnight, and then stored at –20°C. RNA was isolated twice independently from each sample using the High Pure RNA Tissue Kit (Roche Applied Science, Indianapolis, IN, USA) following the manufacturer’s instructions. For each RNA preparation, the concentration of RNA was determined using a spectrophotometer and the concentration of RNA

### Table 1: Composition and nutrient content of pre-feed and test diets (as fed basis)

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>%</th>
<th>Pre-feed (experiments 1 and 2)*</th>
<th>Test diet (experiment 1)*</th>
<th>Test diet (experiment 2)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Milo</td>
<td>54.30</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Corn</td>
<td>–</td>
<td>60.08</td>
<td>49.57</td>
<td></td>
</tr>
<tr>
<td>Soybean meal</td>
<td>15.00</td>
<td>34.58</td>
<td>39.72</td>
<td></td>
</tr>
<tr>
<td>Soy concentrate&lt;sup&gt;a&lt;/sup&gt;</td>
<td>10.96</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Corn starch</td>
<td>10.00</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Soybean oil</td>
<td>3.00</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Cellulose</td>
<td>2.45</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Dicalcium phosphate</td>
<td>1.72</td>
<td>1.86</td>
<td>4.94</td>
<td></td>
</tr>
<tr>
<td>Animal fat</td>
<td>–</td>
<td>1.86</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Calcium carbonate</td>
<td>0.87</td>
<td>0.91</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Methionine hydroxy analog&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.53</td>
<td>0.09</td>
<td>0.33</td>
<td></td>
</tr>
<tr>
<td>Sodium bicarbonate</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>0.45</td>
</tr>
<tr>
<td>Salt</td>
<td>0.42</td>
<td>0.38</td>
<td>0.12</td>
<td></td>
</tr>
<tr>
<td>Zn-free mineral mix&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.10</td>
<td>0.10</td>
<td>0.10</td>
<td></td>
</tr>
<tr>
<td>L-lysine HCl, 78%</td>
<td>0.24</td>
<td>–</td>
<td>0.09</td>
<td></td>
</tr>
<tr>
<td>Magnesium sulfate 7H&lt;sub&gt;2&lt;/sub&gt;O</td>
<td>0.14</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Threonine</td>
<td>0.12</td>
<td>–</td>
<td>0.02</td>
<td></td>
</tr>
<tr>
<td>DL-methionine</td>
<td>–</td>
<td>0.08</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Vitamin premix&lt;sup&gt;d&lt;/sup&gt;</td>
<td>0.05</td>
<td>0.05</td>
<td>0.05</td>
<td></td>
</tr>
<tr>
<td>Tryptophan</td>
<td>0.08</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Etoxyquin</td>
<td>0.01</td>
<td>0.01</td>
<td>0.01</td>
<td></td>
</tr>
<tr>
<td>Choline</td>
<td>0.01</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

**Notes:**<sup>a</sup> Contains 3,150 kcal/kg ME, 22.5% CP, 19 mg/kg Zn (analyzed), experiment 1, 24 mg/kg Zn (analyzed), experiment 2, 0.8% Ca, 0.44% available P<sup>b</sup>;<sup>c</sup> contains 3,000 kcal/kg ME, 22.0% CP, 21 mg/kg Zn (analyzed), 0.82% Ca, 0.47% available P, 0.94% phytate (predicted);<sup>b</sup> contains 3,071 kcal/kg ME, 23.0% CP, 27 mg/kg Zn (analyzed), 1.2% Ca, 1.0% available P, 1.2% phytate (predicted);<sup>c</sup> Ca 946, 84.0% CP (ADM Decatur, IL, USA);<sup>c</sup> contains 0.94% phytate (predicted);<sup>d</sup> profam 646, 84.0% CP (ADM Decatur, IL, USA);<sup>c</sup> available P;<sup>d</sup> 88% methionine hydroxy analog, provides 88% methionine activity (Novus International Inc.);<sup>c</sup> provides per kilogram of diet: Mn 60 mg; Cu 8 mg; selenium 0.15 mg; iron 80 mg; iodine 0.35 mg;<sup>c</sup> provides the following (mg/kg diet): retinyl acetate, 2.4; cholecalciferol, 0.063; DL- α tocopheryl acetate, 10; vitamin B<sub>6</sub>, 0.014; riboflavin 6.5; niacin 37.5; pantothenic acid 10.0; menadione 2.0; folic acid 0.9; pyridoxine 3.5; thiamine 1.8; and biotin 0.15.

**Abbreviations:** CP, crude protein; ME, metabolizable energy.
was adjusted to a maximum of 0.5 mg/mL by dilution with elution buffer. The RNA samples were either used immediately, or frozen on dry ice and stored at −80°C until use.

First-strand complementary DNA synthesis was performed using the Transcriptor Reverse Transcriptase (Roche Applied Science), using the instructions supplied by the manufacturer. Each first-strand synthesis reaction contained 0.5 µg of total RNA. The reverse transcription was performed in a thermocycler using the following program: a 90-second denaturation step at 95°C; annealing for 30 seconds at 40°C; 30 minutes of complementary DNA synthesis at 55°C; and enzyme inactivation by 5 minutes denaturation at 85°C. The reaction product was concentrated by ethanol precipitation, rinsed, and dried. The sample was then resuspended in 400 µL of nuclease-free water and A260/A280 was measured to ensure that complementary DNA concentration in each sample would fall within the range of concentration usable by the real time-polymerase chain reaction (PCR) assay.

MT mRNA (normalized by 18S rRNA) was measured by real-time PCR, as follows. MT mRNA and 18S rRNA levels were measured by real-time PCR on a Roche LightCycler, using the LightCycler FastStart DNA Master HybProbe Kit (Roche Molecular Systems, Alameda, CA, USA) with 0.5 µM of each primer and 0.2 µM of each TaqMan probe. Primers and probes are shown in Table 2. The parameters of the assay were 42 cycles of 10 seconds at 95°C and 40 seconds at 60°C. While MT expression is inducible by Zn in many tissues, 18S rRNA expression was not Zn-inducible (data not shown). MT mRNA levels therefore were normalized in each sample by 18S rRNA levels, as a loading control. In addition, each PCR run included a known reference standard, from small intestinal cells from a chick fed a low-Zn diet. Data analysis was performed by RelQuant software (Roche Molecular Systems). This software automatically computes the concentrations between the target (MT) and a standard (18S rRNA), and then normalizes this ratio to a previously established external reaction standard curve which corrects for the individual reaction efficiency differences between the MT and 18S assays. The MT expression level was determined twice for each original intestinal sample (one for each independent RNA preparation), and the two values were averaged.

### Statistical analyses

Pen means were used as the experimental units for all variables evaluated. For performance measures, all analyses of variance were performed using PROC GLM of SAS version 9.1 (SAS Institute Inc., Cary, NC, USA) appropriate for a randomized complete block design.\(^46\) Statistical differences of treatment means comparisons were made with Fisher’s protected least significant difference test. For bioavailability measures, MT and tibia Zn (total Zn and Zn concentration) were regressed on supplemental Zn intake using predicted dietary Zn concentrations. Zn bioavailability was determined using \(\text{ZnSO}_4 \cdot \text{H}_2\text{O}\) as a standard by means of multiple linear regression and slope-ratio methodology.\(^47-49\) Standard errors were calculated for each regression coefficient. In experiment 1, the REG procedure of SAS version 9.1 was used to test whether the relationship between tibia Zn and supplemental Zn intake was linear or quadratic for each Zn source. When the quadratic effect was significant, a non-linear procedure of SAS (PROC NLIN) was used to determine the breakpoint using a model involving two linear splines with a plateau wherein the dependent variable, total tibia Zn (µg) or tibia Zn concentration (µg/g), was regressed on supplemental Zn intake (mg).\(^31,50\) This non-linear model defines both a linear response range and the inflection point. Levels falling below the inflection points were used to determine Zn bioavailability using the estimate statement of PROC GLM of SAS version 9.1, with \(\text{ZnSO}_4 \cdot \text{H}_2\text{O}\) as the standard. Simple linear regression (PROC GLM) was used to compare \(\text{ZnSO}_4\) slopes between experiments 1 and 2 because tibia Zn concentration intercepts were significantly different between experiments. A non-linear procedure of SAS (PROC NLIN) was used to compare slopes, breakpoints, and plateau values between experiments 1 and 2 for Zn-HMTBa. Statistical differences of treatment mean comparisons were made with Fisher’s protected least significance based on a probability of \(P<0.05\).

### Results

**Experiment 1**

There were no significant source or treatment effects on days 8–14 on weight gain, feed conversion, or tibia weight (Table 3).
Table 3: Response of chicks fed graded levels of Zn sulfate or Zn chelate in a typical C-SBM diet (experiment 1)\textsuperscript{a,b}

<table>
<thead>
<tr>
<th>Zn source\textsuperscript{a}</th>
<th>Weight gain, g</th>
<th>Gainfeed, g/kg</th>
<th>Tibia weight\textsuperscript{b}, g</th>
<th>Supplemental Zn intake (day 14), mg\textsuperscript{e}</th>
<th>Tibia Zn\textsuperscript{c} concentration (\mu g/g)</th>
<th>Tibia Zn\textsuperscript{c} total (\mu g)</th>
<th>MT expression, relative units\textsuperscript{d}</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None</td>
<td>215</td>
<td>630.4</td>
<td>1.21</td>
<td>0</td>
<td>96.8</td>
<td>116</td>
</tr>
<tr>
<td>5</td>
<td>ZnSO\textsubscript{4}</td>
<td>215</td>
<td>635.5</td>
<td>1.33</td>
<td>1.7</td>
<td>100.3</td>
<td>132</td>
</tr>
<tr>
<td>10</td>
<td>ZnSO\textsubscript{4}</td>
<td>217</td>
<td>637.9</td>
<td>1.23</td>
<td>3.4</td>
<td>113.3</td>
<td>138</td>
</tr>
<tr>
<td>15</td>
<td>ZnSO\textsubscript{4}</td>
<td>230</td>
<td>658.8</td>
<td>1.37</td>
<td>5.2</td>
<td>124.3</td>
<td>170</td>
</tr>
<tr>
<td>20</td>
<td>ZnSO\textsubscript{4}</td>
<td>211</td>
<td>635.4</td>
<td>1.30</td>
<td>6.6</td>
<td>134.3</td>
<td>174</td>
</tr>
<tr>
<td>30</td>
<td>ZnSO\textsubscript{4}</td>
<td>223</td>
<td>665.5</td>
<td>1.37</td>
<td>10.0</td>
<td>141.3</td>
<td>193</td>
</tr>
<tr>
<td>5</td>
<td>Zn chelate</td>
<td>214</td>
<td>648.7</td>
<td>1.17</td>
<td>1.7</td>
<td>108.3</td>
<td>128</td>
</tr>
<tr>
<td>10</td>
<td>Zn chelate</td>
<td>207</td>
<td>641.4</td>
<td>1.33</td>
<td>3.2</td>
<td>113.7</td>
<td>151</td>
</tr>
<tr>
<td>15</td>
<td>Zn chelate</td>
<td>219</td>
<td>642.0</td>
<td>1.35</td>
<td>5.1</td>
<td>144.2</td>
<td>193</td>
</tr>
<tr>
<td>20</td>
<td>Zn chelate</td>
<td>226</td>
<td>662.3</td>
<td>1.34</td>
<td>6.8</td>
<td>152.0</td>
<td>202</td>
</tr>
<tr>
<td>30</td>
<td>Zn chelate</td>
<td>231</td>
<td>665.1</td>
<td>1.37</td>
<td>10.4</td>
<td>142.8</td>
<td>192</td>
</tr>
</tbody>
</table>

Notes: Data represent means of six replicate groups (12 replicate groups for the zero supplemental Zn treatment) of eight male chicks during the period of 8–14 days post-hatching. Tibia Zn (both left and right) was measured in two birds per replicate on day 14. MT was measured in one bird per replicate on day 11. Zn-unsupplemented C-SBM diet contained 21 mg/kg diet of Zn, 0.82% Ca, and 0.47% available P. Tibia weight and Zn values are expressed on a dry-bone basis; both ZnSO\textsubscript{4} \textsubscript{2} and Zn chelate were provided as feed-grade sources. Zn chelate was in the form of Zn methionine hydroxy analog (Novus International Inc.); using all levels of Zn sulfate and the 0.5, 10, and 15 mg/kg diet Zn levels of Zn chelate, multiple regression of tibia Zn concentration (\(\mu g/g\), Y) on supplemental Zn intake from Zn sulfate (X\textsubscript{1}) and Zn chelate (X\textsubscript{2}) was: Y = 95.6 (+2.67)X\textsubscript{1} + 5.00 (+0.534)X\textsubscript{2} + 8.26 (+1.051)X\textsubscript{1}X\textsubscript{2}; R\textsuperscript{2} = 0.64 (n=66). Bioavailability of chelated Zn relative to Zn sulfate (100%) was 165% (P=0.0009); using all levels of Zn sulfate and the 0.5, 10, and 15 mg/kg diet Zn levels of Zn chelate, multiple regression of total tibia Zn (Y) on supplemental Zn intake (mg) from Zn sulfate (X\textsubscript{1}) and Zn chelate (X\textsubscript{2}) was: Y = 113.7 (+4.3)X\textsubscript{1} + 8.66 (+0.87)X\textsubscript{2} + 13.93 (+1.71)X\textsubscript{1}X\textsubscript{2}; R\textsuperscript{2} = 0.67 (n=66). Bioavailability of chelated Zn relative to Zn sulfate (100%) was 161% (P=0.001); using only 0, 15, and 30 mg/kg diet Zn levels of Zn sulfate and Zn chelate, multiple regression of IB-normalized MT expression (relative units, Y) on supplemental Zn intake (mg) from Zn sulfate (X\textsubscript{1}) and Zn chelate (X\textsubscript{2}) was: Y = 1.82 (+2.55) + 0.92 (+0.46)X\textsubscript{1} + 2.52 (+0.45)X\textsubscript{2} + 0.534 (+0.111)X\textsubscript{1}X\textsubscript{2}; R\textsuperscript{2} = 0.44 (n=36). Bioavailability of chelated Zn relative to Zn sulfate (100%) was 248% (P=0.009).

Abbreviations: C-SBM, corn-soybean meal; SEM, standard error of the mean; MT, metallothionein.

Tibia Zn (\(\mu g\)) was regressed against supplemental Zn intake (mg) for each source. For Zn sulfate, the relationship between total tibia Zn and supplemental Zn intake was linear (Figure 1A; P<0.0001), whereas for chelated Zn the relationship was quadratic (Figure 1A; P=0.0006). A breakpoint of 5.9 (+0.77) mg of supplemental Zn intake was determined for chelated Zn, which equates to 17.4 mg supplemental Zn/kg diet (38.4 mg total dietary Zn/kg) for this Zn source. Levels below the breakpoint for chelated Zn (0–15 mg Zn/kg diet supplemental Zn) and all levels of Zn sulfate were used to determine the slope (total tibia Zn regressed on supplemental Zn intake) for each source using multiple regression. The slopes of the two sources (Zn sulfate slope 8.66; Zn chelate slope 13.93), and thus their RBVs were significantly different (P<0.001; Figure 1A and Table 3). With the total tibia Zn response to Zn sulfate set at 100%, slope-ratio analysis estimated that the RBV of Zn chelate was 161% (Figure 1A and Table 3). A similar Zn RBV (165%, P=0.0009) was also obtained when tibia Zn concentration (\(\mu g/g\)) was regressed on supplemental Zn intake (mg; Table 3). Small intestinal MT mRNA expression (relative units) was also regressed on supplemental Zn intake (mg). As with tibia Zn, the slopes of the two sources (Zn sulfate slope 0.92; Zn chelate slope 2.28), and thus their RBVs were significantly different (P=0.009; Figure 1B). With the MT response to Zn sulfate set at 100%, the estimated RBV of Zn from Zn chelate was 248% (Figure 1B and Table 3).

Experiment 2

There was no Zn source or treatment effect on weight gain, feed efficiency, or tibia weight (Table 4). However, compared with experiment 1, weight gain and feed intake were substantially reduced as a result of the elevated Ca and P levels. Tibia Zn (both concentration [\(\mu g/g\)] and total Zn [\(\mu g\)]) responded linearly (P<0.05) to supplemental Zn intake for both Zn sources; however, similar to experiment 1, tibia Zn (concentration and total) in birds fed chelated Zn responded linearly only up to 15 mg/kg supplemental Zn (Figure 2A and 3A; and Table 4). Furthermore, tibia Zn concentration reached a similar plateau in both experiments, although this plateau was only reached with chelated Zn (147 \(\mu g/g\) in experiment 1; 149 \(\mu g/g\) in experiment 2; Figure 3A). Multiple linear regression slope-ratio analysis indicated that the slope of the total tibia Zn (\(\mu g\)) curve was 441% (P=0.0063) for chelated Zn relative to Zn sulfate (Figure 2A and Table 4), whereas the RBV estimate for tibia Zn concentration (\(\mu g/g\)) curve for chelated Zn (using only chelated Zn levels below the breakpoint) was 307% (P=0.0066) relative to Zn sulfate (Table 4). Slope-ratio analysis of small intestinal MT mRNA expression indicated that the estimated
bioavailability of chelated Zn was 426% ($P=0.0041$) relative to Zn sulfate (Figure 2B and Table 4).

**Differential effects of Ca/P excess on Zn source**

As shown in Figure 3A, the tibia Zn (µg/g) slopes for Zn chelate were not different (8.32 and 9.97 for Zn chelate in experiments 1 and 2, respectively; $P=0.42$) between experiments 1 and 2, indicating little or no antagonism by the elevated Ca and P. In fact, the slope was numerically higher (19.8% increase) in experiment 2. In contrast, there was a 40% reduction in slope (4.86 and 2.91 in experiments 1 and 2, respectively; $P=0.086$) for Zn sulfate in the presence of elevated Ca and P (Figure 3B). Similar results were seen when total tibia Zn (µg) was compared (data not shown); the Zn sulfate bioavailability (slope 8.66 versus 2.89 for ZnSO$_4$, experiments 1 versus 2, respectively; $P<0.0001$) was reduced by the antagonism much more dramatically (66.6% reduction) than the Zn chelate (slope 13.93 versus 12.77 for Zn chelate, experiments 1 versus 2, respectively; $P=0.57$, or 8.3% reduction). These results suggest that the Zn sulfate was antagonized by elevated Ca and P to a much greater extent than the Zn chelate. Consistent with these results, the tibia Zn breakpoint (y coordinate) did not change appreciably in response to elevated Ca and P when the Zn chelate was fed (147 versus 149 µg/g; Figure 3A). Although the x-breakpoint coordinates appear to be different (6.25 mg supplemental Zn in experiment 1 versus 3.46 mg supplemental Zn in experiment 2), these breakpoints (based on total dietary concentrations) are, in fact, quite similar: 18 versus 16 mg supplemental Zn/kg diet, or 39 versus 43 mg total Zn/kg diet for experiments 1 and 2, respectively.

Note that a plateau for tibia Zn concentration was not reached for Zn sulfate in either trial, but if one assumes that the threshold for tibia Zn concentration when Zn sulfate is fed would be the same as it is when Zn chelate is fed (148 µg/g, the average of the y coordinate from breakpoint estimates obtained from Figure 3A), then one can calculate the amount of Zn sulfate required to meet this threshold from best-fit equations (see Figure 3 legend for equation). Our calculations indicate that in the presence of elevated Ca and P, 10.23 mg supplemental Zn intake from Zn sulfate (equates to 46 mg supplemental Zn/kg diet or 73 mg total Zn/kg diet; experiment 2) would be necessary to reach this threshold, compared with only 3.46 mg for Zn chelate. This represents a threefold difference in amount of Zn needed (Zn sulfate versus Zn chelate) to maximize tibia Zn concentration (µg/g tibia). This estimate (10.23/3.46 = 2.96, or 296%) agrees closely with the 307% RBV estimate determined for tibia Zn concentration in experiment 2 by the slope-ratio methodology (Table 4). In the absence of elevated Ca and P (experiment 1), the amount of Zn sulfate necessary to maximize tibia Zn concentration was calculated to be 10.58 mg supplemental Zn, which equates to 32 mg supplemental Zn/kg diet or 53 mg total Zn/kg diet, whereas the plateau was reached at 6.25 mg supplemental Zn intake for the Zn chelate (Figure 3A). Thus, the bioavailability for Zn chelate is calculated to be (10.58/6.25 = 1.69)
Table 4 Response of chicks fed graded levels of Zn sulfate or Zn chelate in a c-sBM diet with elevated Ca and P (experiment 2)\(^a\)

<table>
<thead>
<tr>
<th>Supplemental Zn, mg/kg</th>
<th>Zn source(^a)</th>
<th>Weight, g</th>
<th>Gain:feed, g/kg</th>
<th>Tibia weight, g</th>
<th>Tibia Zn concentration (\mu\text{g/}g)</th>
<th>Tibia Zn total (\mu\text{g/}g)</th>
<th>MT expression, relative units(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None</td>
<td>158</td>
<td>666.0</td>
<td>0.99</td>
<td>0</td>
<td>117.5</td>
<td>115.4</td>
</tr>
<tr>
<td>15</td>
<td>ZnSO(_4)</td>
<td>146</td>
<td>662.3</td>
<td>0.93</td>
<td>3.27</td>
<td>128.3</td>
<td>117.6</td>
</tr>
<tr>
<td>30</td>
<td>ZnSO(_4)</td>
<td>149</td>
<td>662.5</td>
<td>0.96</td>
<td>6.64</td>
<td>137.7</td>
<td>130.2</td>
</tr>
<tr>
<td>7.5</td>
<td>Zn chelate</td>
<td>164</td>
<td>674.8</td>
<td>1.06</td>
<td>1.80</td>
<td>127.4</td>
<td>136.0</td>
</tr>
<tr>
<td>15</td>
<td>Zn chelate</td>
<td>143</td>
<td>637.2</td>
<td>0.97</td>
<td>3.25</td>
<td>146.8</td>
<td>150.5</td>
</tr>
<tr>
<td>30</td>
<td>Zn chelate</td>
<td>138</td>
<td>669.0</td>
<td>0.91</td>
<td>6.06</td>
<td>149.2</td>
<td>134.6</td>
</tr>
<tr>
<td>Pooled SEM</td>
<td></td>
<td>8.6</td>
<td>17.7</td>
<td>0.05</td>
<td>0.22</td>
<td>6.5</td>
<td>9.2</td>
</tr>
</tbody>
</table>

Notes: \(\mu\)g = µg; \(\gamma\) = µg, Y) on supplemental Zn intake (mg) from Zn sulfate (X\(^1\)) and chelated Zn chelate (X\(^2\)) was: \(Y=115.1 \pm (15.4)0.0041+3.458 (\pm 0.41)0.07% X_1 +12.774 (\pm 3.912)X_2; R^2=0.30 (n=30).\) Bioavailability of chelated Zn relative to Zn sulfate (100%) was: 307% (X\(^1\)), 1\% (X\(^2\)).

Abbreviations: C-sBM, corn-soybean meal; SEM, standard error of the mean; MT, metallothionein.

Discussion

The data from our study indicate that a chelated Zn form is more bioavailable than Zn sulfate in standard balanced diets, and the bioavailability of chelated Zn relative to Zn sulfate increases dramatically in the presence of added Ca and P as antagonists. Consistent with this finding, the tibia Zn data suggest that Zn sulfate appeared to be antagonized by elevated Ca and P, but chelated Zn was not. Indeed, the slope for Zn sulfate was 40% lower in experiment 2 when compared with experiment 1, suggesting the Zn sulfate was antagonized by excess Ca and P. In contrast, the slope for chelated Zn was not different between experiment 2 and experiment 1, indicating that the Zn chelate was not antagonized by excess Ca and P. Collectively, these findings demonstrate the potential advantages of a chelated trace mineral over an inorganic salt, especially under dietary conditions where antagonisms are present.

With regard to plausible explanations for the observed difference in bioavailability, several possibilities exist. One theory, proposed by Kratzer and Vohra, is that chelates have the ability to compete with phytic acid or other antagonists such as Ca and P, for its Zn-binding capacity.\(^{51}\) The Zn contained within the chelate forms a soluble complex with Zn and, consequently, is available to the animal. In contrast, once complexed with phytate or other divalent minerals, the Zn present in inorganic sources is functionally unavailable. Chelates have stronger chemical bonds relative to those in inorganic trace metals, ie, compare the coordinate, covalent bond formed between the two ligands and metal, versus ITMs possessing a weaker ionic bond.\(^{52}\) Thus, chelates are more resistant to antagonisms. An alternative possibility is that organic Zn sources are absorbed via peptide or amino acid transport systems, resulting in higher digestibility and bioavailability.\(^{53}\)

The published data concerning advantages of OTM versus ITM bioavailability are mixed. Some publications report significantly greater bioavailabilities of certain OTMs compared with ITMs,\(^{24,31,54–56}\) whereas many report no differences.\(^{23–26,57}\) Indeed, Schlegel et al recently published a meta-analysis of RBV studies combining a variety of different organic Zn sources, and concluded that, overall, organic Zn sources are not different in bioavailability from inorganic sources.\(^{17}\) The chelated Zn used in the current study was not part of this meta-analysis. These inconsistencies could be due to differences in chemical characteristics (and thus bioavailability) between different OTM forms, or could merely be a reflection of flaws in experimental design that prevent the detection of real differences. It should be noted that the supplemental Zn levels in many of these experiments were beyond the linear response range, or above the tissue Zn breakpoint, which can minimize differences between sources.\(^{31,57,58}\) Multiple papers, for example, have reported no difference in RBV between Zn sulfate and Zn methionine when supplemented at...
high levels.\textsuperscript{31,34,35} The lack of difference in Zn bioavailability at high levels of supplementation is likely due to homeostatic mechanisms at the level of Zn absorption. Expression levels of Zn transporter proteins required for uptake (primarily Zip4 in humans and mice) and export (ZnT1) are both modulated by Zn status of the tissues.\textsuperscript{1,59-62} Zip protein expression increases in deficiency and decreases at excess; the ZnT transporters are modulated in the opposite manner. When a given tissue (for example, the tibia) has reached peak Zn concentrations, net Zn uptake will decrease through these mechanisms. Thus, lack of a tibia Zn difference between Zn sources at high levels of supplementation, above the tibia Zn inflection point, likely simply reflect a downregulation of net Zn import by that tissue rather than an inherent difference in bioavailability per se.

Faster growth rates of poultry and swine over the last two decades have been accompanied by substantial increases in the incidence and severity of a variety of skeletal and other

---

**Figure 2** Regression of total tibia Zn (\(\mu g\)) (A) or small intestinal MT mRNA expression (relative units) (B) on supplemental Zn intake (mg) from chicks fed elevated Ca and P (experiment 2).  
**Notes:** Zn chelate was provided as Zn methionine hydroxy analog (Novus International Inc.). (A) Using all levels of Zn sulfate and the 0, 7.5, and 15 mg/kg Zn levels of Zn chelate, multiple regression of total tibia Zn (\(\mu g, Y\)) on supplemental Zn intake (mg) from Zn sulfate (\(X\)) and Zn chelate (\(X_2\)) was: \( Y=111.48 (\pm 7.40) +2.893 (\pm 1.76)X_1 +12.774 (\pm 3.912)X_2, R^2=0.30 (n=30) \). Bioavailability of chelated Zn relative to Zn sulfate (100%) was 44\% (\(P=0.0063\)). (B) Multiple regression of MT mRNA (relative units, \(Y\)) on supplemental Zn intake (mg) from Zn sulfate (\(X\)) and Zn chelate (\(X_2\)) was: \( Y=0.41 (\pm 1.8) +0.92 (\pm 0.98)X_1 +3.92 (\pm 1.10)X_2, R^2=0.33 (n=36) \). Bioavailability of chelated Zn relative to Zn sulfate (100%) was 42\% (\(P=0.0041\)). For both panels A and B, \(n=6\) replicate groups of eight male chicks per replicate for each treatment.  
**Abbreviation:** MT, metallothionein.

---

**Figure 3** Regression of tibia Zn concentration (\(\mu g/g\)) on supplemental Zn intake (mg) from Zn chelate (A) or Zn sulfate (B) in chicks fed elevated Ca and P (experiment 2) or typical Ca and P levels (experiment 1).  
**Notes:** Zn chelate was provided as Zn methionine hydroxy analog (Novus International Inc.). (A) For Zn chelate, breakpoints were determined using a model involving two linear splines with a plateau. The maximum tibia Zn concentration (\(\mu g/g\)) achieved in both trials was similar [eg, the \(Y\) breakpoint coordinate was 147 \(\mu g/g\) (experiment 1) or 149 \(\mu g/g\) (experiment 2)]. The slopes for Zn chelate were also not different (\(P=0.42\)) between experiments 1 and 2. 8.32 for experiment 1 (typical Ca and P) and numerically higher (9.97) for experiment 2 (elevated Ca and P). Simple linear regression equations for experiments 1 and 2 were \(Y=95.4 +8.3226 (\pm 1.10)X\), and \(Y=114.5 +9.9717 (\pm 2.90)X\), respectively. The breakpoints 6.25 mg (experiment 1) and 3.46 mg (experiment 2) of supplemental Zn correspond to total dietary concentrations of 39 and 43 mg total Zn/kg diet for experiments 1 and 2, respectively. (B) Regression of tibia Zn concentration (\(\mu g/g\)) on supplemental Zn intake (mg) from Zn sulfate in chicks fed elevated Ca and P (experiment 2) or typical Ca and P levels (experiment 1). For experiment 1, the regression equation was: \(Y=96.6 (\pm 2.5) +4.859 (\pm 0.49)X\), \(R^2=0.71\). For experiment 2, the regression equation was \(Y=118.2 (\pm 4.8) +2.913 (\pm 1.11)X\), \(R^2=0.30\). Simple linear regression was used to compare slopes between experiments 1 and 2, because intercepts were different (\(P<0.0001\)). Slopes also tended to be different (\(P=0.086\)). This represents a 40\% reduction in Zn bioavailability for Zn sulfate between experiments 1 and 2.
structural problems, including lameness, bone breakage, tibial dyschondroplasia in poultry, and osteochondrosis in pigs, which are often attributed to poor mineral nutrition.\(^\text{63-66}\) As a result of these issues, trace minerals are often fed at levels that far exceed published NRC requirements.\(^\text{42}\) Despite higher feeding rates, these structural problems persist, likely due to poor mineral bioavailability and mineral–mineral antagonisms resulting from feeding high mineral concentrations. One might predict that feeding trace mineral forms that resist antagonism and are more bioavailable would reduce the incidence of these problems.

A minor limitation of most Zn bioavailability trials is that comparisons between Zn sources are made at deficient or marginal levels of Zn intake. Consequently, it is debated by some that the bioavailability estimates determined at deficient or marginal levels of Zn intake may not be applicable to commercial situations, wherein typical Zn levels exceed Zn requirements by two- to threefold.\(^\text{42}\) Due to homeostatic mechanisms discussed previously (vide supra), little to no differences in bioavailability (as measured by bone Zn or MT) occur at dietary Zn intakes above the requirement, but the advantages in bioavailability are still evident in other biological measurements. Despite the lack of observed differences in this study between Zn sources for animal performance (eg, weight gain, feed intake) or bone Zn at levels above the breakpoint or commercially relevant Zn concentrations, the superior bioavailability of Zn chelate observed at low Zn intake is associated with numerous physiological benefits under commercial conditions. For example, significant advantages of chelated ZnHMTBa, in combination with Mn and CuHMTBa versus ITMs have been demonstrated in turkeys and broilers in field trials, wherein commercial levels of trace minerals were compared. In studies comparing iso-Zn, Cu, and Mn HMTBa versus ITMs, improvements included increased bone strength and width, improved foot pad score, reduced incidence of tibial dyschondroplasia, and reduced incidence of synovitis.\(^\text{267}\) In addition, in a recent commercial broiler trial, birds fed reduced Zn, Cu, and Mn HMTBa (32, 8, and 32 mg/kg diet, respectively) had significantly improved footpad scores relative to broilers fed commercial levels of ITM Zn, Cu, and Mn (100, 125, and 90 mg/kg diet, respectively).\(^\text{68}\) Studies in broilers also demonstrated reductions in bacterial chondronecrosis with osteomyelitis with Zn, Cu, and Mn HMTBa supplementation (64:16:64 mg/kg diet, respectively) versus ITM (100:125:90 mg/kg diet, respectively).\(^\text{69}\) It has recently been reported that sows fed a 50:50 mixture of OTM:ITMs (Zn, Cu, and Mn HMTBa) exhibited a significant reduction in their overall culling rate when compared with control animals fed similar mineral concentrations as 100% inorganic mineral control (165:16:38 mg/kg diet; ZnO, CuSO\(_4\), and MnO, respectively).\(^\text{70}\)

In addition to improved skeletal integrity, chelated mineral sources also provide improved immunity,\(^\text{71-74}\) decreased oxidative stress,\(^\text{72,74}\) and decreased environmental burden.\(^\text{68}\) Furthermore, trace mineral studies comparing Zn, Cu, and Mn HMTBa (individually) versus corresponding sulfates in laying hens reported significant increases in eggshell thickness, Haugh units (a measure of increased egg white height associated with increased freshness and extended shelf-life), and enzyme activity including ceruloplasmin, carbonic anhydrase, and Mn superoxide dismutase.\(^\text{75}\) Thus, reported advantages of chelated minerals over inorganic mineral sources are related to improved structural and skeletal integrity, improved immune function, increased enzyme activity, and decreased oxidative stress. Given the marked changes that have occurred with today’s commercial broilers and turkeys (eg, improved genetic selection, faster growth rates, and birds being grown to heavier market weights), it seems appropriate for future NRC poultry committees to consider recommending the use of chelated minerals for their demonstrated potential in reducing egg breakage (laying hens), tibial dyschondroplasia, synovitis, footpad lesions, chondronecrosis with osteomyelitis, and other issues associated with fast growth in poultry.

### Table 5: Relative bioavailability values (RBVs) of Zn from Zn chelate versus Zn sulfate as affected by Ca and P level\(^\text{a,b}\)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Experiment 1 (typical Ca and P)</th>
<th>P-value</th>
<th>n</th>
<th>Experiment 2 (elevated Ca and P)</th>
<th>P-value</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ZnSO(_4) Slope ± SE</td>
<td>Zn chelate Slope ± SE</td>
<td>RBV(^c)</td>
<td>ZnSO(_4) Slope ± SE</td>
<td>Zn chelate Slope ± SE</td>
<td>RBV(^c)</td>
</tr>
<tr>
<td>Total tibia Zn, µg</td>
<td>8.66±0.87</td>
<td>13.93±1.71</td>
<td>161</td>
<td>0.001</td>
<td>66</td>
<td>2.89±1.76</td>
</tr>
<tr>
<td>Tibia Zn concentration, µg/g</td>
<td>5.00±0.53</td>
<td>8.26±1.05</td>
<td>165</td>
<td>0.0009</td>
<td>66</td>
<td>3.46±1.28</td>
</tr>
<tr>
<td>MT mRNA, relative units</td>
<td>0.92±0.46</td>
<td>2.28±0.45</td>
<td>248</td>
<td>0.009</td>
<td>36</td>
<td>0.92±0.98</td>
</tr>
</tbody>
</table>

Notes: \(^a\)Multiple regression of total tibia Zn, tibia Zn concentration, and MT mRNA expression in small intestine on supplemental Zn intake; Zn chelate, Zn methionine hydroxy analog chelate (Novus International Inc.); \(^b\)Zn-unsupplemented corn-soybean meal diet contained 21 mg Zn/kg, 0.83% Ca and 0.47% available P in experiment 1. In experiment 2, the corn-soybean meal diet contained 27 mg/kg Zn, 1.2% Ca, and 1.0% available P; \(^c\)bioavailability of Zn sulfate set at 100%.

Abbreviations: SE, standard error; MT, metallothionein.
Surprisingly, the tibia Zn concentrations were higher for birds fed the elevated Ca and P diets (experiment 2; unsupplemented or low Zn treatments) compared with birds fed normal Ca and P (experiment 1), until they reached a common plateau (Figure 3). The excesses of both Ca and P in experiment 2 reduced feed intake and body weight, resulting in smaller tibias and, given the similar tibia Zn content, a higher tibia Zn concentration. Similar tibia Zn concentrations ([µg/g], but not total tibia Zn [µg]), between the two experiments (at higher Zn intake) was not expected, but we believe this can be explained by differential partitioning of Zn to the tissues along with the homeostatic mechanisms discussed above. Zn deficiency in the young (eg, applies to livestock, pets, and humans) is characterized primarily by retardation of whole-body growth rather than by changes in tissue Zn content.76

With Zn deficiency, the body reduces intake in an attempt to maintain Zn concentrations in tissues: enzyme activity and organ/tissue concentrations are prioritized over growth. Zn concentrations of some tissues (eg, blood, hair, bone, testes, liver), but not others (eg, brain, lung, muscle, heart) are very sensitive to changes in Zn intake;76 consequently, Zn is partitioned, preferentially, to some tissues versus others. In chicks, for example, approximately 35% of whole-body Zn is stored in the bone, even though the bone only comprises 19% of dry body weight.77 Thus, we believe that, in the case of Zn deficiency imposed in experiment 2, Zn was preferentially targeted to the bone, likely at the expense of some other tissues, until it reached the plateau. In contrast to the differing tibia Zn concentrations in birds fed diets without supplemental Zn, the plateau was very similar between experiments (147 versus 149 µg/g for tibia Zn concentration in experiments 1 and 2, respectively), suggesting that homeostatic mechanisms are working to ensure optimal concentrations of Zn in the bone.

Although no Zn source differences in weight gain, feed efficiency, or tibia weight were observed in experiments 1 and 2, there were significant differences in these measurements between experiments, most likely attributed to the excess of Ca and P. It is widely known that excesses of Ca and P or imbalanced Ca:P ratios depress weight gain.31,78 However, previous studies utilizing C-SBM diets have clearly demonstrated improved Zn status between ITM and OTM Zn sources, as measured by Zn bioavailability differences or antioxidant status, yet show no significant difference in animal performance (eg, bodyweight or weight gain).30,31,73 There were no skeletal issues or lameness observed in our studies, possibly due to the short duration of our study, and/or due to only a marginal Zn deficiency.

Dietary antagonists such as phytic acid, fiber, sulfates, high levels of other trace minerals such as Cu, and potentially high levels of Ca and/or P are common in livestock diets. A Ca level of 4.5% is not uncommon in laying hen diets, nor is 1% Ca uncommon in dairy diets, and high concentrations of Ca and P are commonly fed to turkeys. Elevated Ca and P levels are also prevalent in pet food.79 Based on a survey of 194 wet and dry dog foods, Ca concentrations ranged from 0.6% to 4.1% (mean 1.4%; median 1.3%) and P concentrations ranged from 0.4% to 2.4% (mean 1.1%; median 1.0%). In comparison, the dietary levels of Ca recommended by the Association of American Feed Control Officials (AAFCO), which sets nutrient guidelines for the pet food industry in the USA, and the NRC are 0.6% and 0.4%, respectively;30,81 the dietary levels of P recommended by AAFCO and the NRC are 0.5% and 0.3%, respectively.80,81 Similarly, based on a survey of 137 cat foods (wet and dry), Ca concentrations ranged from 0.5% to 3.5% (mean 1.3%; median 1.2%) and P concentrations ranged from 0.5% to 2.5% (mean 1.1%; median 1%). In comparison, the dietary levels of Ca recommended by AAFCO and the NRC are 0.6% and 0.29%, respectively,80,81 and the dietary levels of P recommended by AAFCO and the NRC are 0.5% and 0.26%, respectively.80,81 Thus, the levels of Ca and P evaluated in experiment 2 (eg, 1.2% Ca, 1.3% total P, 1% available P) would not be uncommon in commercial pet foods. As such, Zn deficiency in dogs and cats may be a concern. Indeed, studies have demonstrated higher Zn requirements in dog foods containing high levels of Ca. One paper reported that puppies fed a standard diet containing 33 mg Zn/kg diet and 1.1% Ca developed signs of Zn deficiency, whereas puppies fed the same level of Zn and 0.3% Ca did not.82 Similarly, others induced a Zn deficiency in puppies fed 20–35 mg Zn/kg diet and 2.64% Ca.83,84 Control puppies fed the same diet but supplemented with 120 mg Zn/kg diet grew normally and demonstrated no clinical signs of Zn deficiency. There have also been a number of reports of naturally occurring Zn deficiency syndromes in dogs fed commercial dog foods.81 Zn deficiency symptoms include poor growth rate and/or significant skin lesions, which initially occur in areas of contact or wear such as foot pads.82 AAFCO recommends a 120 mg Zn/kg diet for dogs, concentrations that are twofold higher than minimum NRC recommendations (eg, 60 mg Zn/kg diet), probably higher because of the high Ca levels and/or phytate present in some commercial dog foods.80 Collectively, these data suggest that certain dietary conditions (high Ca and P) potentially induce Zn deficiency in dogs and cats. Our data suggest that feeding a chelated Zn form could prevent antagonism-induced
Zn deficiency. Interestingly, published data have shown that another chelated Zn form was able to resist Ca-induced Zn antagonism in dogs.\textsuperscript{55}

Our study had some limitations, strengths, and difficulties. One limitation was the lack of control treatments (typical Ca and P concentrations) in experiment 2. Our comparison of experiments 1 and 2 (Figure 3), for example, was confounded by trial. It would have been more appropriate to compare Zn bioavailability between Zn sources under dietary conditions of low Ca/P versus elevated Ca/P within the same trial. Nonetheless, other researchers, using similar C-SBM basal diets (without antagonists) and similar commercial poultry strains (Ross White versus Cobb 500 in our study), yielded similar linear response ranges, breakpoints, and slopes. Thus, the statistical methodology is repeatable between studies and different researchers; thus, we believe our comparisons between experiments 1 and 2 and our conclusions are valid.

For example, Jondreville et al also utilized a linear plateau model to define breakpoints and slopes for tibia Zn concentration (expressed as µg/g) for Zn sulfate, and their results were in close agreement with our trial (eg, breakpoints were 51 versus 53 mg Zn/kg diet (see “Results”; the breakpoint for Zn sulfate was predicted, not determined in our study), and their slope for Zn sulfate was 4.48 versus 5.00 in our study).\textsuperscript{58}

Despite these limitations, this study utilized robust experimental and statistical methodologies, in commercially relevant diets, to elucidate the bioavailability differences between a chelated Zn form and Zn sulfate. Defining the linear response range, the statistical design of our study, and use of C-SBM diets were some of the strengths of our study. Slope-ratio multiple regression analyses is a sensitive statistical methodology used to assess bioavailability (more powerful than pair-wise comparison procedures), but also it has its difficulties, which we attempted, where possible, to address. A linear response range is necessary in order to compare slopes, and it is critical to define the response change in order to ensure treatment doses do not fall in the plateau range. In the case of C-SBM diets, it is especially difficult to formulate a Zn-deficient diet. Typical Zn concentrations in SBM, in our experience, range from 44 mg to 125 mg Zn/kg; thus, it is necessary to screen multiple lots of SBM to identify lots low enough in Zn to create low Zn C-SBM basal diets. In our study, basal diets varied between 21 mg and 27 mg Zn/kg diet; the breakpoint for bone Zn for chelated Zn was 38 mg Zn/kg diet, so the linear response range was quite narrow (11–17 mg/kg Zn). Furthermore, due to the heterogeneity and low Zn concentrations of our diets, it can be difficult for analyzed Zn to agree closely with predicted values (analytical variance for Zn is 20%).\textsuperscript{80} It would be more convenient to use semi-purified diets for Zn bioavailability studies, thus achieving lower dietary Zn concentrations and wider response ranges. However, we believed it was critical that our experimental diets simulate commercially relevant diets in order to obtain data that would be meaningful in the real world. Additionally, the presence of phytate (common in cereal grains and legumes) is an important antagonism that reduces Zn bioavailability, thus maximizing bioavailability differences between inorganic and chelated Zn sources. For example, Wedekind et al compared the bioavailability of an OTM (Zn methionine) versus Zn sulfate in a purified amino acid diet devoid of phytate and fiber and also compared these same Zn sources in a C-SBM diet.\textsuperscript{31} The bioavailability of Zn methionine relative to Zn sulfate was markedly different (117% in the amino acid diet and 206% in the C-SBM diet).

In the presence of antagonisms (ie, phytate, fiber, and/or elevated Ca and P), bioavailability differences between OTMs and ITMs are increased. Thus, the basal diet used to assess Zn bioavailability is critical and dietary characteristics such as phytate, fiber, Ca, and P levels, should simulate commercial conditions. Lastly, the advantages of chelated minerals are often overlooked. A recent meta-analysis concluded no differences between OTMs and ITMs.\textsuperscript{57} Thus, an additional strength of our study was, with careful attention to study details, our ability to show a bioavailability advantage of this particular Zn chelate versus Zn sulfate.

In summary, the bioavailability of a chelated Zn source relative to Zn sulfate was compared utilizing a Zn depletion–repletion model, with two measures of Zn bioavailability assessed (tibia Zn and MT mRNA). The results of this study indicate that chelated Zn provided more bioavailable Zn than inorganic Zn. The greater bioavailability of chelated versus inorganic Zn sources under conditions of dietary antagonisms may be especially important to livestock and pets wherein high levels of Ca and P may be present. In addition, this advantage of chelates demonstrated under conditions of elevated Ca and P, may also be present under other dietary antagonisms, such as phytate, excess Cu, excess Fe, and others.

Acknowledgments
The authors wish to thank B Wuelling and M Wehmeyer for assisting with the conduct of the trial, and Cindy Atwell and Terra Wineman for assistance with sample collection.

Disclosure
PMF, JLE, and KJW are employees of Novus International Inc. (Saint Charles, MO, USA) which manufactures and...
markets OTM products, including Zn chelated to 2-hydroxy-4-(methylthio)butanoic acid (Mintrex® Zn). JDR was an employee of Novus during the course of the study, analysis of the data, and preparation of the manuscript (current affiliation: Department of Global Regulatory and Nutrition Science, Mead Johnson Nutrition, Evansville, IN 47721 USA).

References
3. Fraker PJ, King LE, Laakko T, Vollmer TL. The dynamic link between the integrity of the immune system and zinc status. J Nutr. 2000;130:13995–1406S.


